{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:43:37Z","timestamp":1777866217281,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI125207"],"award-info":[{"award-number":["T32 AI125207"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA221204-01"],"award-info":[{"award-number":["U54 CA221204-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA75903"],"award-info":[{"award-number":["R01 CA75903"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.074","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T08:05:44Z","timestamp":1564646744000},"page":"5177-5184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment"],"prefix":"10.1016","volume":"37","author":[{"given":"Sara R.","family":"Privatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-0079","authenticated-orcid":false,"given":"Brianna L.","family":"Bullard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.074_b0005","unstructured":"Anonymous. HIV\/AIDS; 2018. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"10.1016\/j.vaccine.2019.07.074_b0010","unstructured":"Anonymous. Tuberculosis (TB); 2019. On World Health Organization. https:\/\/afro.who.int\/health-topics\/tuberculosis-tb."},{"key":"10.1016\/j.vaccine.2019.07.074_b0015","unstructured":"Anonymous. WHO|10 facts on malaria; 2016. On World Health Organization. https:\/\/www.who.int\/features\/factfiles\/malaria\/en\/."},{"key":"10.1016\/j.vaccine.2019.07.074_b0020","unstructured":"Anonymous. WHO|Data and statistics; 2018. On World Health Organization. https:\/\/www.who.int\/hiv\/data\/en\/."},{"key":"10.1016\/j.vaccine.2019.07.074_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/08830185.2013.823420","article-title":"Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection","volume":"33","author":"Chen","year":"2014","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0030","doi-asserted-by":"crossref","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin","volume":"7","author":"Alexander","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.074_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205139","article-title":"First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1","volume":"13","author":"Stephenson","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.07.074_b0040","first-page":"163","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Exp Rev Vaccin"},{"key":"10.1016\/j.vaccine.2019.07.074_b0045","doi-asserted-by":"crossref","first-page":"e73313","DOI":"10.1371\/journal.pone.0073313","article-title":"Low seroprevalent species D adenovirus vectors as influenza vaccines","volume":"8","author":"Weaver","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.074_b0050","doi-asserted-by":"crossref","first-page":"e0160341","DOI":"10.1371\/journal.pone.0160341","article-title":"HIV-1-Specific antibody response and function after DNA prime and recombinant adenovirus 5 Boost HIV vaccine in HIV-Infected subjects","volume":"11","author":"Gach","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.074_b0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans","volume":"211","author":"Baden","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.074_b0060","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/s41598-018-35755-z","article-title":"Efficacy of a T cell-biased adenovirus vector as a Zika virus vaccine","volume":"8","author":"Bullard","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.07.074_b0065","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0070","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.074_b0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.074_b0080","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1016\/j.vaccine.2016.07.033","article-title":"Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits","volume":"34","author":"Choudhry","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.074_b0085","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.074_b0090","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs","volume":"24","author":"Alonso-Padilla","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2019.07.074_b0100","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Step Study Protocol TEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.074_b0105","doi-asserted-by":"crossref","first-page":"e1002181","DOI":"10.1371\/journal.pmed.1002181","article-title":"The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (DENGVAXIA): a model comparison study","volume":"13","author":"Flasche","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.07.074_b0110","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.074_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1743-422X-11-25","article-title":"High prevalence and diversity of species D adenoviruses (HAdV-D) in human populations of four Sub-Saharan countries","volume":"11","author":"Pauly","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2019.07.074_b0120","doi-asserted-by":"crossref","first-page":"e0145260","DOI":"10.1371\/journal.pone.0145260","article-title":"Adenovirus specific pre-immunity induced by natural route of infection does not impair transduction by adenoviral vaccine vectors in mice","volume":"10","author":"de Andrade","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.074_b0125","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1099\/jgv.0.000978","article-title":"Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56","volume":"99","author":"Duffy","year":"2018","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v8030078","article-title":"A novel vaccine approach for Chagas disease using rare adenovirus serotype 48 vectors","volume":"8","author":"Farrow","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.07.074_b0140","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2019.07.074_b0145","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3201\/eid2206.151898","article-title":"Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013\u20132014","volume":"22","author":"Scott","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.074_b0150","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jmv.24382","article-title":"Molecular epidemiology and surveillance of circulating rotavirus and adenovirus in Congolese children with gastroenteritis","volume":"88","author":"Mayindou","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4161\/hv.27238","article-title":"Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors","volume":"10","author":"Weaver","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.074_b0160","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/JVI.02950-14","article-title":"Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors","volume":"89","author":"Abbink","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0165","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.074_b0170","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1016\/j.vaccine.2016.09.043","article-title":"Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions","volume":"34","author":"Yang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.074_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12985-018-1049-9","article-title":"Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates","volume":"15","author":"Zhang","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2019.07.074_b0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2019.07.074_b0185","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1097\/INF.0000000000001909","article-title":"Age of infection with Kaposi sarcoma-associated Herpesvirus and subsequent antibody values among children in Uganda","volume":"37","author":"Nalwoga","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.07.074_b0190","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/jmv.24546","article-title":"Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children","volume":"88","author":"Olp","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.07.074_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2013friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2019.07.074_b0200","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2019.07.074_b0205","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","article-title":"Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China","volume":"29","author":"Sun","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:13:59Z","timestamp":1777536839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19309958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":41,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19309958"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.074","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}